BioOutsource is a leading provider of contract testing services to the global biopharmaceutical and biotechnology industry.
Our core offering includes a comprehensive suite of services to support the testing of biologic drugs and vaccines throughout preclinical testing, manufacturing and lot release. In particular, BioOutsource specialise in biosimilar testing services for monoclonal antibodies.
Our scientists possess unrivalled scientific and regulatory expertise to help solve the complex challenges encountered during the development of biosimilars, biologics and vaccines.
At BioOutsource, we assess the quality and safety of biologics, advancing drug candidates through each phase of the drug development pathway by:
- Reduce time to market – Most comprehensive range of off-the-shelf assays for biosimilar development
- Innovative technical expertise – Industry leading technical expertise in bioanalytical and biosafety testing services. As well as in-house R&D department constantly adding to our testing services
- Quality assurance – Quality driven results and regulatory insight for data generation
- Dedicated client support – Single point of contact for clients with regular updates, support and advice
Our experts and client managers work closely with clients, adding value to the process through scientific insights and regular communication and updates.
To Continue Building Analytical Capabilities for Testing Drugs and Vaccines Glasgow, UK – April 27, 2016: Sartorius Stedim BioOutsource, a leading provider of contract testing services to the biopharmaceutical industry, is pleased to announce that it is looking to almost double the scientific workforce at its Glasgow facilities in 2016. The new staff will help More
How Providing Comprehensive Data Can Accelerate Drug Development Glasgow, UK – April 21, 2016: Sartorius Stedim BioOutsource today announced that its scientific experts will be presenting a live webinar about optimizing biosimilar analysis on Thursday, June 2, at 3 pm BST, 10 am EDT. The webinar is essential listening for researchers who want to understand More
Sartorius Stedim BioOutsource Introduces Assays for Testing Biosimilarity of Three Leading Biologics
New ready-to-use assays enable quick and simple generation of precise biosimilar comparability data Glasgow, UK – March 22, 2016: Sartorius Stedim Biotech (SSB), an international leading supplier for the biopharmaceutical industry, presents a range of ready-to-use assays for testing Actemra, Stelara and Lucentis biosimilars. The new assays, launched by SSB’s subsidiary Sartorius Stedim BioOutsource, will More